The pleasing business trend in the first two months of 2006 justifies our optimism.

We are convinced that merging the two companies will create a health care heavyweight of international standing with a strong market position based on an innovative product portfolio and a well-stocked pipeline.

Our strategic realignment towards innovation and growth has brought a sustained improvement in the Bayer group's earning power.

Our take is really cautious optimism, the business is really building momentum. We're still encouraged by the U.S. revenue outlook.

It's the thing in itself that justifies it.

The trend will likely continue through the first half.